The FDA warns patients and clinicians about unapproved and compounded versions of GLP-1 receptor agonist drugs like semaglutide and tirzepatide used for weight loss. Because compounded drugs do not undergo FDA review for safety, effectiveness, or quality, the agency says their use carries risks and should be limited to patients whose needs cannot be met by approved products. The FDA also lists red flags for consumers buying weight-loss medications via telehealth and offers recommendations for safe prescribing and purchasing.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.